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Objectives: To discuss the role of disodium etidronate therapy for prevention of calcium
phosphate vesical calculi in persons with spinal cord injury, who have hypercalciuria and
biochemical evidence of increased bone resorption.
Setting: Regional Spinal Injuries Centre, Southport, UK.
Methods: A 21-year-old male sustained paraplegia (T-10; ASIA scale: A) in a road traﬃc
accident in June 2001. He had an indwelling urethral catheter until the end of August 2001,
when he started self-catheterisation. He developed bladder stones and electrohydraulic
lithotripsy (EHL) was performed in May 2002. All stone fragments were removed. Recurrence
of vesical calculi was noted in October 2002. These stones were fragmented by lithoclast
lithotripsy in two sessions, in December 2002 and February 2003; all stone fragments were
removed at the end of the second session. This patient reverted to indwelling catheter drainage
when vesical calculi recurred. In September 2003, X-ray of the abdomen showed recurrence of
vesical calculi. By February 2004, the stones had increased in size and number. EHL of vesical
calculi was again performed in April 2004. Complete clearance was achieved.
Results: A 24-h urinalysis detected hypercalciuria – 18.7mmol/day (reference range: 2.5–7.5).
Biochemical analysis of vesical calculus revealed calcium phosphate (85%) and magnesium
ammonium phosphate (15%). Plasma C-terminal telopeptide (CTX) was increased – 1.06 ng/ml
(reference range: 0.1–0.5 ng/ml). Free deoxypyridinoline/creatinine ratio (fDPD/Cr) in urine was
also increased – 20.2 (reference range: 2.3–5.4). In April 2004, this patient was prescribed
disodium etidronate 400mg day. Nearly 3 months after commencing therapy with etidronate,
plasma CTX decreased to 0.87 ng/ml. fDPD/Cr in urine also decreased to 12.4. After 4 months
of etidronate therapy, 24-h urinary calcium excretion had decreased to 6.1mmol/day.
Conclusion: Etidronate (400mg daily) is a very eﬀective inhibitor of calcium phosphate
crystallisation. Etidronate decreased urinary excretion of calcium, an important factor in
prevention of calcium phosphate bladder stones. Etidronate therapy is not a substitute for other
well-established methods for prevention of vesical calculi in spinal cord injury patients, for
example, large ﬂuid intake, avoiding long-term catheter drainage. Intermittent therapy with
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etidronate may be considered in selected patients, in whom hypercalciuria persists after
instituting nonpharmacological therapy for an adequate period, for example, early mobilisation,
weight-bearing exercises, and functional electrical stimulation. However, possible side eﬀects of
etidronate, and the fact that etidronate is not licensed in United Kingdom for prevention of
urolithiasis, should be borne in mind.
Spinal Cord (2005) 43, 269–277. doi:10.1038/sj.sc.3101713; Published online 18 January 2005
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Introduction
Common predisposing factors for the occurrence of
bladder stones in persons with spinal cord injury are:
stasis of urine in the bladder, urinary infection, and
long-term indwelling catheter drainage.1 It is generally
believed that metabolic abnormalities do not play a
pivotal role in the causation of bladder stones in persons
with spinal cord injury. Lamid et al2 found no signi-
ﬁcant diﬀerence in the incidence of bladder stone
formation in patients with hypercalciuria compared
with those with normal urinary calcium excretion.
In regions endemic for urolithiasis, metabolic ab-
normalities have been described in patients with vesical
calculi. Singh et al3 studied 59 stone formers with
bladder stones in northwest India, where urolithiasis is
endemic. A 24-h urinary excretion of calcium, oxalic
acid, inorganic phosphorus, magnesium, and citric acid
revealed presence of hypercalciuria and hyperoxaluria in
18.6 and 44.1%, respectively, while 11.9% of patients
had both abnormalities. Hypomagnesuria and hypo-
citraturia were present in 67.8 and 69.5%, respectively,
while 45.7% had both of these abnormalities. Normal
urine chemistry in respect of parameters studied, was
observed only in 1.7% of cases. Of the 59 patients, one
risk factor was present in 15.2% of patients, while
83.1% had two or more risk factors.3
Bisphosphonates inhibit calcium oxalate crystal
growth in vitro. Older- and newer-generation bisphos-
phonates inhibited calcium oxalate vesical lithiasis in
male Sprague–Dawley rats, and the inhibitory eﬀect of
bisphosphonates was demonstrable at relatively infre-
quent dosing intervals in vivo.4 We present a spinal cord
injury patient with recurrent bladder stones, hypercal-
ciuria, and biochemical features of increased bone
resorption, who was prescribed disodium etidronate.
Case report
A 21-year-old male sustained fracture dislocation of T-7
and T-8 and developed paraplegia at T-10 level (ASIA
scale - A) in a road traﬃc accident in June 2001. Spinal
ﬁxation was performed with USS system from T-5 to
L-l. He was managing his bladder by indwelling catheter
until the end of August 2001, when he started self-
catheterisations along with oxybutynin by mouth. X-ray
of abdomen, taken in September 2001, showed a very
faint radio opaque shadow in the region of the urinary
bladder (Figure 1).
The USS system was removed in November 2001. He
was discharged from the spinal unit in January 2002. In
March 2002, he developed urine infection and started
leaking urine between catheterisations. X-ray of abdo-
men showed two large radio opaque shadows in the
region of urinary bladder (Figure 2). There were no
calculi in the kidneys or ureters. Flexible cystoscopy
conﬁrmed the presence of vesical calculi. Electro-
hydraulic lithotripsy was performed in May 2002. All
stone fragments were removed. Intravenous urography,
performed in October 2002, showed calculi in the
urinary bladder. There was prompt excretion of contrast
by both kidneys; there was no hydronephrosis. X-ray of
urinary bladder, taken in December 2002, showed
several calculi in the bladder (Figure 3). These stones
were fragmented by lithoclast lithotripsy in two sessions,
in December 2002 and February 2003. All stone
fragments were removed at the end of the second
session of lithotripsy. Although he started self-catheter-
isations along with oxybutynin by mouth, he reverted to
indwelling catheter drainage when vesical calculi re-
Figure 1 X-ray of abdomen, taken on 28 September 2001,
shows a faintly radio opaque calculus projected over the
bladder
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curred. In September 2003, he attended the spinal unit
with a history of repeated blocking of his indwelling
urethral catheter. X-ray of abdomen showed recurrence
of vesical calculi (Figure 4). By February 2004, the
stones had increased in size and number (Figure 5).
Electrohydraulic lithotripsy of vesical calculi was
performed in April 2004. Complete clearance was
achieved.
Bacteriuria was noticed in this patient on many
occasions. In August 2001, urine microbiology showed
Pseudomonas aeruginosa. In September 2001, urine
culture yielded P. aeruginosa and Enterococcus faecalis.
In February 2003, urine microbiology showed Staphylo-
coccus aureus and Escherichia coli. In March 2004,
E. coli was grown in urine, and this organism was resistant
to gentamicin, ciproﬂoxacin, ceftazidime, and tazocin.
A 24-h urine biochemistry analysis, performed on 3
October 2003, detected hypercalciuria of 18.7mmol/day
(reference range: 2.5–7.5). Repeat measurement of 24-h
urinary calcium, performed after dietary restriction of
calcium, showed a value of 14.1mmol/day. Biochemical
analysis of a vesical calculus demonstrated calcium
phosphate (85%) and magnesium ammonium phos-
phate (15%).
The 24-h urinary excretion of urate was 2.0mmol/day
(reference range: 1.2–3.0), that of oxalate was 265 mmol/
Figure 2 X-ray of abdomen, taken on 15 March 2002, shows
two larger radio opaque calculi in the bladder
Figure 3 X-ray of pelvis, taken on 12 December 2002, shows
several calculi in urinary bladder located around the Foley
catheter balloon
Figure 4 X-ray of pelvis, taken on 29 September 2003, shows
recurrence of bladder stones
Figure 5 X-ray of pelvis, taken on 26 February 2004, shows
the stones have grown in size and are located around the
balloon of Foley catheter
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day (reference range: 189–477 mmol/day) and that of
phosphate was 21.8mmol/day (reference range: 12.9–
42.0mmol/day).
Serum sodium, potassium, urea, creatinine, alkaline
phosphatase, calcium, and phosphate were within
normal range (Table 1). Thyroid proﬁle showed
euthyroid status. TSH: 0.6mU/l (reference range:
0.3–5.0mU/l); Free T-4: 19.9 pmol/l (reference range:
9.0–24.0 pmol/l).
Plasma C-terminal telopeptides (CTX) was increased
– 1.06 ng/ml (reference range: 0.10–0.50 ng/ml). Free
deoxypyridinoline/creatinine ratio (fDPD/Cr) in urine
was also increased – 20.2, reference range: 2.3–5.4.
Parathyroid hormone was 1.6 pmol/l (reference range:
1.1–6.9 pmol/l); this value was appropriate for the
adjusted calcium at that time. 1,25 Vitamin D was
within normal limits (74 pmol/l: reference range:
43–144 pmol/l). In April 2004, this patient was pres-
cribed disodium etidronate 400mg/day.
Nearly 3 months after commencing therapy with oral
disodium etidronate, plasma CTX level had decreased to
0.87 ng/ml (reference range: 0.1–0.5 ng/ml). fDPD/Cr in
urine also decreased to 12.4 (reference range: 2.3–5.4).
But both plasma CTX and free fDPD/Cr in urine were
still high when compared to the reference range in
healthy adults. After 4 months of etidronate therapy,
24-h urinary calcium excretion decreased to 6.1mmol/
day, which was within the normal range.
Bone mineral densitometry of lumbar spine (L-l–L-4)
performed in July 2004, showed T score of 1.53, which
denoted osteopaenia. T score of left hip was 3.70,
which indicated osteoporosis. In September 2004,
patient was advised to take etidronate intermittently
(2 weeks on and 12 weeks oﬀ). The 24-h urine calcium,
plasma CTX and urine fDPD/Cr will be checked every
12 weeks.
Discussion
In the past, etidronate therapy for urolithiasis led to side
eﬀects5,6 probably because etidronate was administered
continuously or, phosphate was also prescribed. Hope-
fully, side eﬀects such as osteomalacia may not occur
with intermittent etidronate therapy, which is repre-
sented by 3–4 months of continuous therapy, followed
by 2 weeks of etidronate and 12 weeks without. This
case raises some important issues in management of
spinal cord injury patients, who develop recurrent
vesical calculi.
 What is the role of bisphosphonates in prevention of
calcium phosphate vesical calculi in spinal cord injury
patients? Diphosphonate had no inhibitory eﬀect on
struvite bladder calculi, which were induced in rats
with an intrarenal injection of urease-producing
human T mycoplasma strain T960.7 Ebisuno et al8
examined the eﬀect of etidronate on the crystallisation
of calcium oxalate, calcium phosphate, and magne-
sium ammonium phosphate using synthetic urine and
measured by an aggregometer. Etidronate aﬀected the
crystallisation of not only calcium phosphate and
calcium oxalate, but also magnesium ammonium
phosphate in synthetic urine. The inhibitory activities
on these crystallisations were detected at extremely
low drug concentrations. Are these observations,
made on synthetic urine, applicable to in vivo situation
in spinal cord injury patients, who develop stones in
urinary bladder?
 Does therapy with bisphosphonate represent ﬁrst-line
therapy of hypercalciuria in spinal cord injury patients?
Or, should spinal cord clinicians focus on nonphar-
macological therapy, for example, early mobilisation,
optimal nutrition (with care to avoid exacerbating
hypercalciuria), weight-bearing exercises, functional
electrical stimulation, cycle ergometry, etc,9 and
prescribe bisphosphonates to selected patients, in
whom hypercalciuria persists after instituting non-
pharmacological therapy for an adequate period.
Several reports in the 1970s suggested that etidronate
disodium might be clinically useful to prevent calcium
stones, but the use of etidronate in the urolithiasis
ﬁeld was discontinued due to adverse eﬀects of this
drug on skeletal turnover and mineralisation.8
Table 1 Results of blood tests
Test Reference range
3 July
2001
5 July
2001
28 September
2001
9 October
2002
12 December
2002
28 September
2003
15 March
2004
15 July
2004
Sodium 133–146mmol/l 135 136 139 141 140 140 141 142
Potassium 3.5–5.2mmol/l 4.2 4.0 4.1 3.8 3.9 3.7 4.2 3.9
Urea 2.3–7.5mmol/l 4.4 4.1 4.5 3.2 4.2 3.8 3.4 2.4
Creatinine 0–135 mmol/l 64 77 77 66 85 73 81 64
Albumin 31–47 g/l 36 36 42 42 48 43 45 39
Calcium 2.20–2.60mmol/l 2.28 2.23 2.40 2.39 2.32 2.19 2.42 2.33
Alkaline
phosphatase
40–120U/l 114 115 72 72 67 66 74 74
Adjusted
calcium
2.20–2.60mmol/l 2.36 2.31 2.36 2.31 2.16 2.13 2.32 2.35
Phosphate 0.80–1.50mmol/l 1.40 1.36 1.41 1.08 1.04 1.07 0.99 1.09
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 Which bisphosphonate should we prescribe and what
should be the duration of treatment with bisphosphonate
for prevention of urinary calculi in spinal cord injury
patients, who show biochemical features of increased
bone resorption? Etidronate, if administered continu-
ously, may lead to abnormal mineralisation of osteoid
and microfractures, which might potentially result in
increased susceptibility to fractures, especially non-
vertebral fractures. Although etidronate prevents
decreases in the bone mineral density in hemiplegic
stroke patients by decreasing the serum calcium
through inhibition of bone resorption and causing a
subsequent increase in the serum 1,25-dihydroxyvita-
min D concentration,10 etidronate has not been
licensed in the United Kingdom to treat persons
with spinal cord injury, who show increased bone
resorption.
 What are the limitations and possible complications of
disodium etidronate treatment in spinal cord injury
patients? Oral amino derivatives of bisphosphonates
may induce dose-related serious gastrointestinal
lesions, especially erosive oesophagitis. Amino-bi-
sphosphonate administration has been also associated
with the sporadic occurrence of uveitis, scleritis and
phlebitis and, in single cases, with irritative reactions
at the skin, peritoneum and pericardium.11 After
some months/years of therapy with etidronic acid for
osteoporosis, some patients developed mood, concen-
tration and memory problems. The complaints
diminished within several weeks after withdrawal of
the drugs, and reappeared after rechallenge.12
Comments by Olof Jonsson (MD, PhD, Professor
of Urology, Department of Urology, Sahlgrenska
University Hospital, S-413 45 Go¨teborg, Sweden)
At the Spinal Cord Injury Centre at Sahlgrenska
University Hospital, Go¨teborg, Sweden, we have about
100 spinal cord injuries per year. The patients arrive at
the Spinal Cord Injury Ward as soon as possible after
the injury. During the stay at the Intensive Care Unit,
they usually have an indwelling catheter but as soon as
possible, clean intermittent catheterisation (CIC) is
instituted. At time of discharge from the Spinal Injury
Ward, 70% of the patients perform CIC and 20% have
normal micturition. Only about 5% of the patients do
have a catheter a` demeure or a suprapubic catheter. At
ﬁrst follow-up, 70% of the patients still perform clean
intermittent catheterisation. The number of patients
with catheter a` demeure or suprapubic catheter is about
10%. The results of the neurourological follow-up 1
year after injury are discussed at a urological conference
and based on this discussion, 30% of the patients are
advised to consider some kind of alteration in their
bladder regimen. The commonest recommendations are
alterations in the mode of performing clean intermittent
catheterisation and addition of anticholinergic treat-
ment. Also 2 years after injury, about 70% of the
patients still are on clean intermittent catheterisation.
Most patients use the LoFric catheter (AstraTech).
Antibiotics are only given when the patient has clinical
signs of urinary tract infection. The bladder is regularly
rinsed with sodium chloride or sodium chloride plus
chlorhexidine in connection with catheterisation.
We very seldom see bladder stones in our patients. This
is probably due to the fact that most patients are on clean
intermittent self-catheterisation. 1 cannot remember in
our practice any single patient, who had a similar bladder
stone problem, as the patient presented in the Clinical case
of the month. Thus, we do not regularly measure the
calcium content of the urine.
In summary, I do not consider bladder stones as a
major problem in our patients. I strongly support the
use of clean intermittent self-catheterisation in these
patients. When an indwelling catheter is used, it should
be changed regularly before encrustations on the surface
of the balloon occur.
Comments by Dr AZ Buczynski (MD, PhD,
Department of Neuro-Urology, Metropolitan
Rehabilitation Centre, Konstancin, Poland)
Thank you for invitation for my comments concerning
this very interesting case. 1 have not had any experience
with the use of disodium etidronate in patients with
paralysis. As far as I know, this drug is mainly used for
postmenopausal osteoporosis in female patients.
According to my experience with cystolithiasis of
paraplegic and tetraplegic patients, a very high percen-
tage of bladder stones in such patients (except those who
have had stones before accident) are struvite stones.
These stones contain ammonium, magnesium, calcium,
and phosphates with increased content of calcium
especially in young men. Prolonged immobilisation,
infections, especially by urea splitting, mainly nosoco-
mial microorganisms, residual urine, and indwelling
catheter are the most important factors for stone
formation in such cases.
Precise removal of bladder stones fragments after
lithotripsy, subsequent exact eradication of infection,
liquidation of residual urine, and keeping urine in low
pH usually prevent recurrent bladder stone formation.
In this particular case presented here, a very abnormal
level of urine calcium and biochemical markers of bone
resorption suggest an explanation for nontypical fre-
quent recurrence of bladder stones. The necessity for
removal of bladder stones in one patient more than
twice in a period of just a couple of years is extremely
rare in my personal experience of hundreds of such
patients (paraplegic and tetraplegic patients with blad-
der stones) during the last 30 years.
Comments by Dr F Grases (PhD, Professor and
Director of the Laboratory of Renal Lithiasis
Research, Institute of Health Sciences Research
(IUNICS), University of Balearic Islands,
Palma de Mallorca, Spain)
Urine is always supersaturated (contains higher
amounts of solute than the maximum total amount that
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can remain indeﬁnitely solved) with respect to calcium
oxalate and depending on its pH value, is also super-
saturated with respect to uric acid (urinary pH inferior
to 5.5) or calcium phosphates (urinary pH superior to
6.0). In spite of this, crystallisation processes (stone
formation) only take place in uncontrolled pathological
situations. The question is, why does crystallisation not
take place indiscriminately in all human urines and yet
only appears in pathological situations? The answer is
now clear. There are four main aspects that must be
considered to explain pathological crystallisation: super-
saturation higher than usual of the crystallising sub-
stance, and/or the presence of heterogeneous nucleants
(crystallisation inducers) as any preformed solid parti-
cles (cellular residues, bacterial debris, etc), and/or
deﬁcit of crystallisation inhibitors (substances that
disturb crystal formation and development), and/or
urinary stasis (the increase of the urinary residence time
in the urinary track obviously increases the possibility of
crystallisation of supersaturated substances). Thus,
in healthy conditions, the presence of crystallisation
inhibitors at adequate concentrations prevents the
development of solid concretions during the urine
permanence in the urinary track. In fact, the crystal-
lisation inhibitors act delaying the crystallisation of
supersaturated substances, avoiding that crystallisation
takes place before the renovation of the corresponding
urine.
If all these aspects are applied to the very interesting
case presented in your paper, the following facts must be
considered:
 The analysis of the calculus revealed calcium phos-
phate (hydroxyapatite)þmagnesium ammonium
phosphate (struvite). The aetiology of these calculi
implies a urinary pH superior to 6.0 (to reach calcium
phosphate supersaturation). The existence of a
persistently elevated urinary pH also favoured bacter-
ial colonisation. In fact, in this patient bacteriuria was
noticed on several occasions (urealitic and nonurea-
litic bacteria). Urealitic bacteria, due to their meta-
bolic activity, still increase the pre-existent urinary pH
and also generate ammonium (as a consequence
magnesium ammonium phosphate is also formed).
Owing to all these mentioned aspects, it is very
important in these patients to avoid urinary pH values
superior to 6.0. For this reason, a strict control of all
dietetic components that increase urinary pH must be
recommended. Thus, these patients must avoid
carbonic beverages (or bicarbonate ingestion), foods
that contain citrate (lemon, orange, kiwi, etc) and
strict vegetarian diets. It would also be important to
perform a regular precise control of urinary pH.
 According to the literature and our experience,
etidronate and other related polyphosphates act as very
eﬀective inhibitors of calcium phosphate crystallisation
at appropriate urinary concentrations. Considering the
low urinary excretion of these products (around 1–2%
of the ingested amounts) and oral etidronate dose of
400mg/day would imply urinary concentrations
around 1–4mg/1. These amounts are high enough to
produce signiﬁcant inhibitory eﬀects, and as a
consequence, etidronate can exert a notable role on
preventing calcium phosphate stone.
 Hypercalciuria constitutes an important risk factor of
calcium oxalate and calcium phosphate stone devel-
opment since it increases supersaturation of these
compounds. The decrease of calciuria by the oral
etidronate therapy constitutes another clear factor for
prevention of calcium phosphate bladder stones.
 Finally, to avoid development of solid particles that
could act as heterogeneous nucleants, when an
indwelling catheter is used, it would be very important
to change the catheter regularly before encrustations
on the surface occur. Of course, a high water intake
(2–3 l/day) is also fundamental to dilute the urine, to
avoid urinary stasis and to carry away all incipient
solid particles formed.
Comments by Ita Pfeferman Heilberg (MD, PhD,
Professor of Nephrology, Nephrology Division,
Federal University of Sa˜o Paulo, Sa˜o Paulo, Brazil)
The present case illustrates that spinal cord injury
patients may develop bladder stones, but this is unlikely
to occur among patients with normal urinary tract.
Therefore, stone formation must have been consequent
to urine stasis, bacterial colonisation and catheter use,
leading to a condition worsened by the presence of bone
resorption-induced hypercalciuria. However, it is clear
that hypercalciuria itself would have induced renal
and not bladder stones if the former factors were not
to be present. In addition, the size of the calculi and
recurrence rate over such a short period of time suggests
that probably these stones have not migrated from the
upper urinary tract but were rather formed within the
bladder. Considering the highly recurrent bladder stone
formation in this patient and given the need for very
frequent urological procedures to remove calculi, I think
that it was wise and cost-eﬀective to search for
metabolic abnormalities in this context, in order to
provide not only treatment but also a preventive
approach.
Early attempts to treat calcium urolithiasis, retarding
the crystal growth of urinary brushite with bisphos-
phonates have been reported in the literature,5,13 but it
seems that the potential bone hazards have overcome
their eﬃcacy on stone formation. Surprisingly, there
were no signiﬁcant changes in urinary calcium in the
latter cited study.
In the present case, etidronate induced a decrease on
bone resorption as expected, and this was evidenced by
the values of speciﬁc biochemical markers; urinary
calcium excretion also decreased. Albeit the treatment
of immobilisation hypercalcaemia with bisphosphonates
is very well established in the literature, and that
alendronate is able to prevent bone loss and avert
hypercalciuria when given in anticipation of a 3 weeks of
Vesical calculi and hypercalciuria in paraplegics
S Vaidyanathan et al
274
Spinal Cord
strict bedrest,14 the potential eﬀect of such drugs in
spinal cord injury patients concerning control of
hypercalciuria remains unknown.
Considering the antiresorptive potency of the distinct
bisphosphonates and their side eﬀects, I think that either
clodronate or the second generation (alendronate) or
even one of the third-generation bisphosphonates would
be a better choice without the need of cyclic therapy.
However, I still cannot say if therapy with bisphos-
phonates represent ﬁrst-line therapy of hypercalciuria in
spinal cord injury patients. It is possible that, as
suggested by the authors of the present case, early
mobilisation, weight-bearing exercises, functional elec-
trical stimulation, etc. if applicable, would be most
useful, and that bisphosphonates could be relegated to a
secondary role in controlling hypercalciuria. Not only
bone densitometry or bone markers but also urinary
calcium must often be determined in order to answer
some of these unsolved questions. Most of the studies
employing this drug do not report the results on urinary
calcium. Another important point to mention is that the
classic prescribed therapy for hypercalciuria (thiazides)
would probably be very diﬃcult to be managed by these
patients due to the enhancement of urinary ﬂow.
In the present case, bisphosphonate would be
indicated even if the bladder stones were not present,
if one considers the profound bone loss (T-score of left
hip of 3.70), leading to osteoporosis. I think that the
clinical course of the present case, namely the evolution
of urinary calcium levels, as well as the rate of new stone
formation, will tell and teach us more than we can ﬁnd
in the literature to date.
Comments by Takahiro Yasui, Keiichi Tozawa,
and Kenjiro Kohri (Department of Nephro-Urology,
Nagoya City University Graduates School of
Medical Sciences, 1 Kawasumi, Mizuho-cho,
Mizuho-ku, Nagoya 467-8601, Japan)
We consider that clear intermittent self-catheterisation is
best for the management of urine in spinal cord injury.
In this particular case, both a high level of hypercalci-
uria and infection explained the frequent recurrence of
bladder stone. Bisphosphonate is eﬀective in decreasing
urinary calcium excretion and bone metabolism by the
domination of osteoclasts. In this case, especially,
bisphosphonate was adequate in the beginning term of
spinal cord injury and for long-term bed rest and
hypercalciuria. Etidronate and other related bispho-
sphonates act as very eﬀective inhibitors of calcium
phosphate crystallisation at an appropriate urinary
concentration in vitro.
Bisphosphonates, which decrease bone resorption,
may possibly be considered in patients with hypercal-
ciuria due to increased bone resorption. Indeed,
alendronate, a new generation bisphosphonate, has
been reported to decrease urinary calcium and satura-
tion with urinary calcium phosphate, so that the values
after immobilisation through bed rest never reach
previously attained levels. The hypocalciuric eﬀect of
bisphosphonates may possibly be of use in certain
patients with increased bone resorption.
Bisphosphonates are classiﬁed by generation accord-
ing to their structural diﬀerences. Etidronate is an old
generation bisphosphonate compound, which has been
used for osteoporosis. It decreases calcium oxalate and
calcium phosphate crystallisation in vitro. However,
etidronate cannot be used to treat urinary stones
because the dosages required preventing stone forma-
tion causes disorders in skeletal turnover and bone
mineralisation, generally. In some studies showing an
eﬀect in chronic stone-formers, the dose necessary to
obtain inhibition of crystal growth in urine was so high
that it could also induce inhibition of skeletal miner-
alisation. Therefore, generally, etidronate should not be
recommended for use in urolithiasis.
Consequently, novel bisphosphonates classiﬁed as a
new generation have been synthesised. They are
pharmacologically 100–l000-fold more potent than
etidronate in terms of bone antiresorptive activity, and
can be clinically applied to tumour-induced hypercal-
caemia and osteoporosis. The P-C-P structure of
bisphosphonates allows considerable variation, either
by changing the two lateral chains on the carbon atom
or by esterifying the phosphate groups. Thus, each
bisphosphonate has unique physicochemical and biolo-
gical characteristics. New generation bisphosphonates
are considered useful for this or similar cases, although
we have no experience with recurrent bladder stone after
spinal injury with hypercalciuria.
Comments by Professor Jean-Jacques Wyndaele
(Centrum Urologische Revalidatie, Universitair
Zieckenhuis Antwerpen, 10 Wilrijkstraat, B 2650
Edgem, Belgium)
Stone formation in patients with spinal cord injury has
a high prevalence. Approximately 6% of spinal cord
damaged patients will develop upper tract calculi
compared with 2% in the general population. There is
no clear relationship between incidence of upper tract
calculi and neurological level. Calculi are rare in patients
with lesion below LI.15 Bladder calculi are much more
prevalent and related to infection and foreign material,
for example, catheters.16
The metabolic changes after spinal cord injury are
important. Calcaemia does not seem to change though
individual cases of dangerous hypercalcaemia have been
described early after injury.17 The other changes in
blood chemistry are known: an increase in phosphate,
alkaline phosphatase, and calcitonin. In the urine,
hypercalciuria is observed from day 2–3 after spinal
cord injury, which reaches normal levels again at month
5–8.
Chronically, the danger for hypercalciuria remains
probably because of the lack of weight bearing on the
bones.17 It is long ago that Issekutz et al18 showed that
long-term standing alone could lower the hypercalciuria.
Moreover, calciuria can be increased by intake of drugs
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such as ammonium chloride, ascorbic acid, hexamine
methionine mandelamine acid.
A high ﬂuid intake is accepted as a prevention
measure, but its limitations have been shown before.19
Infection has a very negative role especially the feared
Proteus infection. The presence of catheters oﬀers
another substrate to stone formation. This case study
shows a positive eﬀect of the use of oral disodium
etidronate in this patient; plasma CTX level has been
decreased. However, it remains to be seen whether
lowering of plasma CTX will be enough to prevent
further stones from developing. We will need an update
after 6 and 12 months.
Comments by Professor B Schurch, (MD, Depart-
ment of Neuro-Urology, Spinal Cord Injury Centre,
University Hospital Balgrist, Zurich, Switzerland)
First of all, we have to admit that we have no experience
with the use of bisphosphonates for para- or tetraplegic
patients. Even though we see about 1000 patients with
neurogenic bladder per year (most of them are spinal
cord injury patients) in our outpatient clinic, the
occurrence of bladder stones seems to be quiet rare
(approximately 3–4/year). In these cases, we do not
routinely perform 24-h urine analyses and therefore,
we cannot comment on the occurrence of metabolic
disorders such as hypercalciuria. We agree to the
common sense that bladder stone-formation results
from repeated infections in combination of indwelling
catheter and neurogenic bladder dysfunction. Our
treatment in such cases is removal of the bladder calculi
and long-term follow-up by ultrasound and/or cysto-
scopy. We try to prevent repeated urine infections by
informing patients the need for regular intermittent
catheterisation. Our protocol comprises of good patient
education, high ﬂuid intake, and lowering the pH of
urine by use of L-methionine. As we have not used
bisphosphonates, we cannot comment on your ques-
tions concerning the use of bisphosphonates. We need
well-designed, randomised, double-blinded studies to
evaluate use of bisphosphonates to prevent bladder
stone-formation in paralytic patients. The question
remains if such a study will be worth the eﬀort,
considering the low incidence of bladder stones in spinal
cord injury patients.
Concluding remarks by United Kingdom team
Although 24-h urinary excretion of calcium decreased
after etidronate therapy, X-ray of abdomen, taken on 16
September 2004, showed a small opacity in pelvis,
indicative of recurrent vesical calculus. This is not
surprising, as this patient continues to have long-term
indwelling urethral catheter drainage of bladder and has
been suﬀering from recurrent urine infection. We failed
miserably in persuading this patient, as well as many
others, to consider intermittent catheterisation as the
preferred option for management of neuropathic blad-
der. We wish we could emulate Dr Olof Jonsson in
Salhgrenska University Hospital, Go¨teborg, Sweden,
where 70% of spinal cord injured patients perform
intermittent catheterisation, only about 5% of the
patients do have a catheter a` demeure or a suprapubic
catheter, and consequently, bladder stones are seldom
seen in spinal cord injured patients.
This patient was prescribed etidronate, but we wish to
emphasise that etidronate has not been licensed in the
United Kingdom either for treatment of increased bone
resorption in persons with spinal cord injury, or for
prevention of urolithiasis. This case illustrates that many
factors contribute to the pathogenesis of vesical calculi
in persons with spinal cord injury. Treatment of
hypercalciuria by etidronate is not suﬃcient by itself
to prevent recurrence of vesical calculi, especially when
other causes, such as, long-term catheter drainage and
recurrent urine infection, have not been dealt with.
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